Category Archives: RCH-01

Replicel’s update from the Stem Cell on the Mesa conference

Replicel gave its presentation today at the Stem Cell on the Mesa Conference.  Although my regular day job meant that I missed the live webcast, Replicel kindly Tweeted its presentation summary to me.

I was expecting the presentation to be dominated by the company’s achilles tendinosis related work, but there was a good amount of information on the male pattern baldness work (RCH-01) too.  As previously discussed on this blog, their phase 2 trials began in Germany in 2014.  However, it seems like the Japanese trials have been delayed and moved from late 2014 to the first half of 2015. Both trials will last for 1 year.

They also presented their completed 6-month phase 1 trial results. Average density across all participants increased 11.8 percent with no side effects.  I wonder if this average density increase figure will go up significantly as they increase dosage and time frame?  I would hope so.

FYI — today and tomorrow, you can listen to some excellent track 1 webcasts and track 2 webcasts from the Mesa Conference.  The future can’t come fast enough.

Replicel and Shiseido update

Yesterday, Replicel announced its financial results for the second quarter of 2014.

The main hair related items of interest were:

  1. Shiseido’s new research center in Japan, already discussed on this blog before.
  2. Replicel anticipating the start of Phase 2 trials for its RCH-01 hair regeneration technology in Germany in the fourth quarter of 2014.
  3. Shiseido also starting Phase 2 trials in Japan in the fourth quarter of 2014.  I was surprised to read that Shiseido is the world’s fourth largest cosmetics company, further lending credibility to Replicel’s technology.

Note that on Replicel’s website, they still have a page where one can volunteer to sign up for their clinical trials provided one resides in Austria or Germany.  It seems like they are limiting enrollment to 160 male volunteers.

The company’s losses increased modestly compared to the same period last year, but there seem to be valid reasons for this as explained in their announcement. Nevertheless, the company’s stock price declined by over 7 percent today as of the time of writing this post.

Replicel (REPCF)’s 1-year daily stock price and volume traded (in 000 shares per day) charts from nasdaq.com:

stock chart

According to a June 2014 report from Allied Analytics, the global regenerative medicine market is expected to grow from $16.4 billion in 2013 to $67.6 billion in 2020 — a stellar outlook.  Besides hair regeneration, Replicel is also involved in tendon regeneration (RCT-01) and skin regeneration (RCS-01) technologies.  The company has stated that its tendon regeneration product is its most important focus, while its skin regeneration product is still in an early research phase of development.

Considering that Replicel uses autologous (one’s own) cells in the regeneration process, the chances of any kind of serious side effects seem minimal.  This has favorable implications for the company passing safety requirements during Phase 2 trials.

It is worth following Replicel’s Facebook page and Replicel’s Twitter feed for more frequent updates.